The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus

Hye Seung Jung, Byung Soo Youn, Young Min Cho, Kang Yeol Yu, Hong Je Park, Chan Soo Shin, Seong Yeon Kim, Hong Kyu Lee, Kyong Soo Park

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Resistin is a protein secreted from adipose tissue that is thought to play a role in insulin sensitivity. We examined the effects of rosiglitazone and metformin on the plasma resistin levels in individuals with type 2 diabetes mellitus. Patients with type 2 diabetes mellitus who showed poor glycemic control with glimepiride (4 mg/d) were randomized to rosiglitazone (4 mg/d) and metformin (500 mg bid) treatment groups. All subjects continued glimepiride treatment as well. The plasma concentrations of resistin were measured at baseline and at 6 months of treatment for both groups. The anthropometric parameters, fasting plasma glucose, HbA1c, total cholesterol, triglyceride, high-density lipoprotein cholesterol, free fatty acids, and adiponectin concentrations were also measured. After 6 months of treatment, the reduction in plasma glucose levels was similar between the 2 groups. There were no significant changes in the lipid profiles of either group during the study period. The plasma resistin levels decreased in the rosiglitazone group (2.49 ± 1.93 vs 1.95 ± 1.59 ng/ml; P < .05) but increased in the metformin group (2.61 ± 1.69 vs 5.13 ± 2.81 ng/ml; P < .05). The plasma adiponectin concentrations were increased in the rosiglitazone group (2.91 ± 1.46 vs 4.23 ± 1.77 μg/ml; P < .05) but were unchanged in the metformin group. In summary, rosiglitazone treatment decreased the plasma resistin levels whereas metformin treatment increased them in patients with type 2 diabetes mellitus showing poor glycemic control with sulfonylurea therapy. These results suggest that the observed changes in plasma resistin levels are not the consequences of improved insulin resistance, nor are they consequences of glycemic control. Considering the potential role of resistin in insulin resistance, decrease in resistin levels may contribute to improving insulin action with rosiglitazone treatment.

Original languageEnglish
Pages (from-to)314-320
Number of pages7
JournalMetabolism: Clinical and Experimental
Volume54
Issue number3
DOIs
StatePublished - 1 Jan 2005

Fingerprint

rosiglitazone
Resistin
Metformin
Type 2 Diabetes Mellitus
glimepiride
Insulin Resistance
Adiponectin
Therapeutics
Glucose
Nonesterified Fatty Acids
HDL Cholesterol

Cite this

@article{a5a0dbefbb144c5db14fb951d5c3a29f,
title = "The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus",
abstract = "Resistin is a protein secreted from adipose tissue that is thought to play a role in insulin sensitivity. We examined the effects of rosiglitazone and metformin on the plasma resistin levels in individuals with type 2 diabetes mellitus. Patients with type 2 diabetes mellitus who showed poor glycemic control with glimepiride (4 mg/d) were randomized to rosiglitazone (4 mg/d) and metformin (500 mg bid) treatment groups. All subjects continued glimepiride treatment as well. The plasma concentrations of resistin were measured at baseline and at 6 months of treatment for both groups. The anthropometric parameters, fasting plasma glucose, HbA1c, total cholesterol, triglyceride, high-density lipoprotein cholesterol, free fatty acids, and adiponectin concentrations were also measured. After 6 months of treatment, the reduction in plasma glucose levels was similar between the 2 groups. There were no significant changes in the lipid profiles of either group during the study period. The plasma resistin levels decreased in the rosiglitazone group (2.49 ± 1.93 vs 1.95 ± 1.59 ng/ml; P < .05) but increased in the metformin group (2.61 ± 1.69 vs 5.13 ± 2.81 ng/ml; P < .05). The plasma adiponectin concentrations were increased in the rosiglitazone group (2.91 ± 1.46 vs 4.23 ± 1.77 μg/ml; P < .05) but were unchanged in the metformin group. In summary, rosiglitazone treatment decreased the plasma resistin levels whereas metformin treatment increased them in patients with type 2 diabetes mellitus showing poor glycemic control with sulfonylurea therapy. These results suggest that the observed changes in plasma resistin levels are not the consequences of improved insulin resistance, nor are they consequences of glycemic control. Considering the potential role of resistin in insulin resistance, decrease in resistin levels may contribute to improving insulin action with rosiglitazone treatment.",
author = "Jung, {Hye Seung} and Youn, {Byung Soo} and Cho, {Young Min} and Yu, {Kang Yeol} and Park, {Hong Je} and Shin, {Chan Soo} and Kim, {Seong Yeon} and Lee, {Hong Kyu} and Park, {Kyong Soo}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.metabol.2004.05.019",
language = "English",
volume = "54",
pages = "314--320",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "3",

}

The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. / Jung, Hye Seung; Youn, Byung Soo; Cho, Young Min; Yu, Kang Yeol; Park, Hong Je; Shin, Chan Soo; Kim, Seong Yeon; Lee, Hong Kyu; Park, Kyong Soo.

In: Metabolism: Clinical and Experimental, Vol. 54, No. 3, 01.01.2005, p. 314-320.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus

AU - Jung, Hye Seung

AU - Youn, Byung Soo

AU - Cho, Young Min

AU - Yu, Kang Yeol

AU - Park, Hong Je

AU - Shin, Chan Soo

AU - Kim, Seong Yeon

AU - Lee, Hong Kyu

AU - Park, Kyong Soo

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Resistin is a protein secreted from adipose tissue that is thought to play a role in insulin sensitivity. We examined the effects of rosiglitazone and metformin on the plasma resistin levels in individuals with type 2 diabetes mellitus. Patients with type 2 diabetes mellitus who showed poor glycemic control with glimepiride (4 mg/d) were randomized to rosiglitazone (4 mg/d) and metformin (500 mg bid) treatment groups. All subjects continued glimepiride treatment as well. The plasma concentrations of resistin were measured at baseline and at 6 months of treatment for both groups. The anthropometric parameters, fasting plasma glucose, HbA1c, total cholesterol, triglyceride, high-density lipoprotein cholesterol, free fatty acids, and adiponectin concentrations were also measured. After 6 months of treatment, the reduction in plasma glucose levels was similar between the 2 groups. There were no significant changes in the lipid profiles of either group during the study period. The plasma resistin levels decreased in the rosiglitazone group (2.49 ± 1.93 vs 1.95 ± 1.59 ng/ml; P < .05) but increased in the metformin group (2.61 ± 1.69 vs 5.13 ± 2.81 ng/ml; P < .05). The plasma adiponectin concentrations were increased in the rosiglitazone group (2.91 ± 1.46 vs 4.23 ± 1.77 μg/ml; P < .05) but were unchanged in the metformin group. In summary, rosiglitazone treatment decreased the plasma resistin levels whereas metformin treatment increased them in patients with type 2 diabetes mellitus showing poor glycemic control with sulfonylurea therapy. These results suggest that the observed changes in plasma resistin levels are not the consequences of improved insulin resistance, nor are they consequences of glycemic control. Considering the potential role of resistin in insulin resistance, decrease in resistin levels may contribute to improving insulin action with rosiglitazone treatment.

AB - Resistin is a protein secreted from adipose tissue that is thought to play a role in insulin sensitivity. We examined the effects of rosiglitazone and metformin on the plasma resistin levels in individuals with type 2 diabetes mellitus. Patients with type 2 diabetes mellitus who showed poor glycemic control with glimepiride (4 mg/d) were randomized to rosiglitazone (4 mg/d) and metformin (500 mg bid) treatment groups. All subjects continued glimepiride treatment as well. The plasma concentrations of resistin were measured at baseline and at 6 months of treatment for both groups. The anthropometric parameters, fasting plasma glucose, HbA1c, total cholesterol, triglyceride, high-density lipoprotein cholesterol, free fatty acids, and adiponectin concentrations were also measured. After 6 months of treatment, the reduction in plasma glucose levels was similar between the 2 groups. There were no significant changes in the lipid profiles of either group during the study period. The plasma resistin levels decreased in the rosiglitazone group (2.49 ± 1.93 vs 1.95 ± 1.59 ng/ml; P < .05) but increased in the metformin group (2.61 ± 1.69 vs 5.13 ± 2.81 ng/ml; P < .05). The plasma adiponectin concentrations were increased in the rosiglitazone group (2.91 ± 1.46 vs 4.23 ± 1.77 μg/ml; P < .05) but were unchanged in the metformin group. In summary, rosiglitazone treatment decreased the plasma resistin levels whereas metformin treatment increased them in patients with type 2 diabetes mellitus showing poor glycemic control with sulfonylurea therapy. These results suggest that the observed changes in plasma resistin levels are not the consequences of improved insulin resistance, nor are they consequences of glycemic control. Considering the potential role of resistin in insulin resistance, decrease in resistin levels may contribute to improving insulin action with rosiglitazone treatment.

UR - http://www.scopus.com/inward/record.url?scp=13844270858&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2004.05.019

DO - 10.1016/j.metabol.2004.05.019

M3 - Article

C2 - 15736108

AN - SCOPUS:13844270858

VL - 54

SP - 314

EP - 320

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 3

ER -